The future of sovereign immunity deals after Allergan ruling

Late last week, the Patent Trial and Appeal Board (PTAB) rejected a Native American tribe’s attempt to dismiss inter partes reviews (IPRs) based on the tribe’s sovereign immunity claims.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Allergan and tribe to appeal PTAB’s immunity decision

2 March 2018 The Saint Regis Mohawk Tribe and Allergan are planning to appeal against the Patent Trial and Appeal Board’s decision rejecting tribal sovereign immunity.

Americas

Native American tribe not entitled to sovereign immunity: PTAB

26 February 2018 The Patent Trial and Appeal Board rejected the Saint Regis Mohawk Tribe’s attempt to dismiss inter partes reviews related to dry-eye treatment Restasis late last week.

Americas

Native American tribe aims to dismiss Allergan patent IPRs

26 September 2017 The Saint Regis Mohawk Tribe has attempted to dismiss inter partes reviews brought by Mylan.